Adams R.J., Albers G., Alberts M.J. et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack // Stroke. - 2008. - Vol. 39. - P. 1647-1652.
Doufekias E., Segal A.Z., Kizer J.R. Cardiogenic and aortogenic brain embolism // J. Am. Coll. Cardiol. -
- Vol. 51. - P. 1049-1059.
European Stroke Organisation (ESO) Executive Committee and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 // Cerebrovasc. Dis. - 2008. - Vol. 25. - P. 457-507.
O’Donnell M.J., Hankey G.J., Eikelboom J.W. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review // Stroke. - 2008. - Vol. 39. - P. 1638-1646.
Singer D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. - 2008. - Vol. 133. - P. 546S-592S.
СПИСОК ЛИТЕРАТУРЫ
Frankel M.R., Morgenstern L.B., Kwiatkowski T. et al. Predicting prognosis after stroke a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke trial // Neurology. -
- Vol. 55. - P. 952-959.
2.Savitz S.I., Fisher M. Future of neuroprotection for acute // Stroke. In the aftermath of the SAINT trials // Ann. Neurol. - 2007. - Vol. 61. - P. 396-402.
Doufekias              E, Segal AZ, Kizer JR. Cardiogenic and aortogenic brain embolism // J. Am. Coll. Cardiol. -
- Vol. 51. - P. 1049-1059.
Harloff              A., Handke M., Reinhard M. et al. Therapeutic strategies after examination by transesophageal echocardiography in 503. patients with ischemic // Stroke - 2006. - Vol. 37. - P. 859-864.
5.Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for // Cochrane Database Syst. Rev. - 2007. - Vol. 4: CD000197.
Candelise              L., Gattinoni M., Bersano A. et al. Stroke-unit care for acute stroke patients: an observational follow-up study // Lancet. - 2007. - Vol. 369. - P. 299-305.
European              Stroke Organisation (ESO) Executive Committee and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 // Cerebrovasc. Dis. - 2008. -
Vol. 25. - P. 457-507.
Marler              JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt- PA stroke study // Neurology. - 2000. - Vol. 55. - P. 1649-1655.
Hacke              W., Kaste M., Bluhmki E. et al. Thrombolysis with alteplase 3. to 4.5.              hours              after acute              ischemic
// N. Engl. J. Med. - 2008. - Vol. 359. - P. 1317-1329.
Vahedi              K., Hofmeijer J., Juettler E. et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials // Lancet Neurol. - 2007. - Vol. 6. - P. 215-222.
11 .Di Tullio M.R., Sacco R.L., Sciacca R.R. et al. Patent foramen ovale and the              risk              of ischemic              stroke in
a multiethnic population // J. Am. Coll. Cardiol. - 2007. - Vol. 49. - P. 797-802.
12.Overell J.R., Bone I., Less K.R. Interatrial septal abnormalities and A meta-analysis of case-control studies // Neurology. - 2000. - Vol. 55. - P. 1172-1179.
13.Serena J., Marti-Fabregas J., Santamarina E. et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study // Stroke. - 2008. - Vol. 39. - P. 31313136.
Windecker              S., Wahl A., Nedeltchev K. et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 750-758.
EAFT              Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor // Lancet. - 1993. - Vol. 342. - P. 1255-1262.
16.Saxena R., Koudstaal P.J. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack // Cochrane Database Syst. Rev. - 2004. - Vol. 2: CD000185.
Hart              R., Pearce L., Miller V. et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: Frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies // Cerebrovasc. Dis. - 2000. - Vol. 10. - P. 39-43.
Nieuwlaat              R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. - 2005. - Vol. 26. - P. 24222434.
Fuster              V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006. guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society // Euro. PACE. - 2006. - Vol. 8. - P. 651-745.
Hylek              E.M., Evans-Molina C., Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation // Circulation. - 2007. - Vol. 115. - P. 26892696.
Connolly              S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W) : a randomised controlled trial // Lancet. - 2006. - Vol. 367. - P. 1903-1912.
Antiplatelet              Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients // BMJ. - 1994. - Vol. 308. - P. 81-106.
Antithrombotic              Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. - 2002. - Vol. 524. - P. 71-86.
Born              G., Patrono C. Antiplatelet drugs // Br. J. Pharmacol. - 2006. - Vol. 147(Suppl.1): S241-S51.
Algra              A., van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin // J. Neurol. Neurosurg. Psychiatry. - 1999. - Vol. 65. - P. 255.
Patrono              C., Garcia Rodriguez L.A., Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis // N. Engl. J. Med. - 2005. - Vol. 353. - P. 2373-2383.
Topol              E., Easton D., Harrington R. et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease // Circulation. - 2003.
Vol. 108. - P. 16-23.
Yusuf              S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation // N. Engl. J. Med. - 2001. - Vol. 345. - P. 494-502.
CAPRIE              Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. - 1996. - Vol. 348. - P. 1329-1339.
Diener              H., Bogousslavsky J., Brass L. et al. Acetylsalicylic acid on a background of clopidogrel in high- risk patients randomised after recent ischaemic stroke or transient ischaemic attack. The MATCH trial results // Lancet. - 2004. - Vol. 364. - P. 331-334.
31 .Bhatt D.L., Fox K.A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1706-1717.
Bhatt D.L., Flather M.D., Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial // J. Am. Coll. Cardiol. - 2007. - Vol. 49. - P. 1982-198.
Diener              H.C., Cuhna L., Forbes C. et al. European Stroke Prevention Study 2: Dipyridamole and acetylsalicyclic acid in the secondary prevention of // J. Neurol. Sci. - 1996. - Vol. 143. - P. 1-13.
Diener              H.C., Darius H., Bertrand-Hardy J.M. et al. Cardiac safety in the European stroke prevention study 2 (ESPS2) // Int. J. Clin. Pract. - 2001. - Vol. 55. - P. 162-163.
ESPRIT              Study Group, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT) : randomised controlled trial // Lancet. - 2006. - Vol. 367. - P. 1665-1673.
36.Sacco R.L., Diener H.C., Yusuf S. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent // N. Engl. J. Med. - 2008. - Vol. 359. - P. 1238-1251.
37.Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Asso-ciation/American Stroke Association Council on // Circulation. - 2006. - Vol. 113: e409-e449.
38.Straus S.E., Majumdar S.R., McAlister F.A. New evidence for stroke prevention: scientific review // JAMA. - 2002. - Vol. 288. - P. 1388-1395.
Lewington              S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61. prospective studies // Lancet. -
- Vol. 360. - P. 1903-1913.
Rashid              P., Leonardi-Bee J., Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review // Stroke. - 2003. - Vol. 34. - P. 2741-2749.
41 .Bosch J., Yusuf S., Pogue J. et al. Use of ramipril in preventing stroke: double blind randomised trial // BMJ. - 2002. - Vol. 324. - P. 699-702.
42.The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease // Arch. Intern. Med. - 2003. - Vol. 163. - P. 1069-1075.
43.Schrader J., Luders S., Kulschewski A. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) // Stroke. - 2005. - Vol. 36. - P. 1218-1226.
Yusuf              S., Diener H., Sacco R. et al. Randomized trial of telmisartan therapy to prevent recurent strokes and major vascular events among 20,332. individuals with recent // N. Engl. J. Med. - 2008. - Vol. 359. - P. 1225-1237.
Diener              HC. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non- valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies // Cerebrovasc. Dis. - 2006.
Vol. 21. - P. 279-293.
Barnett              H.J., Taylor D.W., Eliasziw M. et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1415-1425.
European              Carotid Surgery T rialists’ Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST) // Lancet. - 1998. - Vol. 351. - P. 1379-1387.
Rothwell              P., Eliasziw M., Gutnikov S. et al. - Carotid Endarterecto-my Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery // Lancet. - 2004. - Vol. 363. - P. 915-924.
Chaturvedi              S., Bruno A., Feasby T. et al. Carotid endarterectomy - an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology // Neurology. - 2005. - Vol. 65. - P. 794-801.
Ringleb              P.A., Allenberg J., Bruckmann H. et al. 30day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial // Lancet. - 2006. - Vol. 368. - P. 1239-1247.
51 .Stingele R., Berger J., Alfke K. et al. Clinical and angiographic risk factors for stroke and death within 30. days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study // Lancet Neurol. - 2008. - Vol. 7. - P. 216-222.
Yadav J.S., Wholey M.H., Kuntz R.E. et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1493-1501.
Mas              J.L., Chatellier G., Beyssen B. et al, for the EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis // N. Engl. J. Med. - 2006. - Vol. 355. - P. 1660-1671.
Kern              R., Ringleb P.A., Hacke W. et al. Stenting for carotid artery stenosis // Nat. Clin. Pract. Neurol. -
- Vol. 3. - P. 212-220.
Eckstein              H.H., Ringleb P., Allenberg J.R. et al. Results of the Stent-Protected Angioplasty versus Carotid 56. Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial // Lancet. Neurol. - 2008. - Vol. 7. - P. 893-902.
Mas              J.L., Trinquart L., Leys D. et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial // Lancet Neurol. - 2008. - Vol. 7. - P. 885-892.
CAVATAS              Investigators. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial // Lancet. - 2001. - Vol. 357. - P. 1729-1737.
Dries              D.L., Rosenberg Y.D., Waclawiw M.A. et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials // J. Am. Coll. Cardiol. - 1997. - Vol. 29. - P. 1074-1080.
Loh              E., Sutton M.S., Wun C.C. et al. Ventricular dysfunction and the risk of stroke after myocardial infarction // N. Engl. J. Med. - 1997. - Vol. 336. - P. 251-257.
Roberts              W.C., Siegel R.J., McManus B.M. Idiopathic dilated cardiomyopathy: analysis of 152. necropsy patients // Am. J. Cardiol. - 1987. - Vol. 60. - P. 1340-1355.
Al-Khadra              A.S., Salem D.N., Rand W.M. et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 749-753.
McAlister              F.A., Ghali W.A., Gong Y. et al. Aspirin use and outcomes in a community-based cohort of 7352. patients discharged after first hospitalization for heart failure // Circulation. - 2006. - Vol. 113. -
P. 2572-2578.
Guazzi              M., Brambilla R., Reina G. et al. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin // Arch. In